Antiverse

Antiverse designs antibodies for challenging therapeutic targets using machine learning.

Cardiff, UK—Founded 2017—Website

£7.4MTotal raised

Antiverse is a techbio company that designs antibodies for complex therapeutic targets using machine learning and cell line engineering. The firm operates facilities in Cardiff, Boston and Prague.

Founders

Murat Tunaboylu

Co-Founder and CEO

Murat is the chief executive officer at Antiverse. He previously held roles at Thermo Fisher Scientific, Deep Science Ventures, and Singer Instrument Co Ltd.

Investors

Seed15 October 2024
£3.5M
i&i Biotech FundLead
Kadmos CapitalLeadFollow-on
IV
InnoSpark Ventures
UKI2S
TV
Tensor VenturesFollow-on
A
AngelHubFollow-on
Series A1 March 2023
£2.5M
I
InnoSpark
A
AngelHub
Kadmos Capital
TS
Tomorrow Scale
TV
Tensor VenturesFollow-on
DS
Deep Science Ventures
Development Bank of WalesFollow-on
Seed15 March 2021
£1.4M
EP
Ed ParkinsonLead
Development Bank of Wales
UI
UKI2S Innovate Accelerator
AC
Angel Co-Investment Fund
TV
Tensor Ventures
Wren Capital
Cambridge Angels
SyndicateRoom

Funding history

Seed15 October 2024

£3.5M

Antiverse secures £3.5m in seed funding led by i&i Biotech Fund and Kadmos Capital to advance antibody discovery.

The latest investment brings total equity financing to £7.2m and will support clinical progression of internal assets.

Series A1 March 2023

£2.5M

Antiverse raises £2.5m from new and existing backers to fund in-house asset development.

The financing was supported by new investors including InnoSpark alongside returning backers such as the Development Bank of Wales.

Seed15 March 2021

£1.4M

Antiverse raises £1.4m in seed funding to advance its AI drug discovery platform.

The seed round was supported by a syndicate of investors including the Development Bank of Wales and the UKI2S Innovate Accelerator to fund platform development and laboratory expansion.